Xuanzhu Biopharmaceutical

2575 · HKEX

Public Market Listing

2575HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for Xuanzhu Biopharmaceutical are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(4 total)
4Total Assets
0Approved
2Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Phase 3
CDK2/4/6Small molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer
Phase 3
ALK / ROS1Small molecule
Non-Small Cell Lung Cancer
Phase 1/2
ROS1/NTRKSmall molecule
Non-Small Cell Lung Cancer
Phase 1
AXL inhibitorSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

9 June 2025Filing acceptedXZP-3287NMPA accepts bireociclib NDA for a third indication
CN, NMPA · Sihuan Pharmaceutical Holdings Group · Source ↗
2 May 2024Filing acceptedXZP-3621NMPA accepts NDA for dexitinib (XZP-3621)
CN, NMPA · Sihuan Pharmaceutical Holdings Group Ltd. · Source ↗

Financial reports

Annual history (3 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$4.2M$26M—$77Mreport ↗
View 2 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2023-FY$0$34M—$42Mreport ↗
2022-FY$0——$76Mreport ↗